Core Viewpoint - Heng Rui Medicine (01276.HK) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HRS-2162 injection, a new generation muscle relaxant antagonist, which will soon commence clinical trials. Currently, there are no similar products approved for sale domestically or internationally [1]. Company Summary - Heng Rui Medicine's subsidiary has received a clinical trial approval for HRS-2162 injection [1]. - HRS-2162 is identified as a new generation muscle relaxant antagonist that can counteract the pharmacological effects of muscle relaxants and rapidly restore muscle tone [1]. - The absence of similar products in the market highlights a potential competitive advantage for Heng Rui Medicine [1].